Sharing ASCT Academic Feast - CSCO Autologous Transplant Working Group 2022 Tour (Jiangxi & Fujian Station) was successfully held

Golden autumn in September, fruitful
.
On September 24, 2022, sponsored by the Chinese Society of Clinical Oncology (CSCO), CSCO Lymphoma Expert Committee and CSCO Leukemia Expert Committee, and hosted by Jiangxi Provincial Cancer Hospital and Union Hospital Affiliated to Fujian Medical University, the 2022 Lecture Tour - Lymphoma Special Session (Jiangxi & Fujian Station) was successfully held
in online form 。 Professor Shuang Yuerong of Jiangxi Provincial Cancer Hospital and Professor Shen Jianzhen of Union Hospital Affiliated to Fujian Medical University were invited to co-chair the conference, and Professor Huang Ruibin of the First Affiliated Hospital of Nanchang University and Professor Liu Tingbo of Union Hospital Affiliated to Fujian Medical University were invited to co-chair the
conference.
At the same time, well-known experts in the field were invited to serve as speakers and commentators to discuss the application and development
of autologous hematopoietic stem cell transplantation (ASCT) in lymphoma.
This article is specially compiled for the key content of the conference for the benefit of readers
.

At the beginning of the conference, the presidents of the conference, Professor Shuang Yuerong and Professor Shen Jianzhen, delivered opening speeches
in turn.
In his speech, Professor Shuang Yuerong said that it is a great honor to have an in-depth discussion with all of you on the role of transplantation in the whole process of lymphoma management, diagnosis and treatment, and I hope that the scholars attending the meeting will be able to gain
something from this study and discussion.
Professor Shen Jianzhen said in his speech that with the improvement of medical level, the advancement of molecular diagnosis technology, and the rich treatment methods, we have gradually entered the era of precision diagnosis and treatment, the era of new drugs, and transplantation has always maintained an important position
for lymphoma patients with strong heterogeneity and high malignancy.
In recent decades, transplantation technology has developed in the direction of good safety and good efficacy, bringing great survival benefits
to patients.
Finally, I would like to thank the CSCO Lymphoma Expert Committee and the CSCO Leukemia Expert Committee for hosting this meeting to promote the rapid progress
of China's transplant technology in the direction of maturity and standardization.

Professor Shuang Yuerong and Professor Shen Jianzhen delivered opening speeches

The academic special session is full of dry goods, and the eyes are overwhelmed! This special session was hosted
by Professor Huang Ruibin.

Professor Huang Ruibin served as the academic moderator

Professor Lin Junfang of the First Affiliated Hospital of Fujian Medical University made a detailed report
on the topic of "2022 EHA MM& Lymphoma ASCT Progress Selection".
Patients with newly diagnosed MM (NDMM) with high-risk cytogenetic factors often relapse after a single ASCT, and tandem ASCT may overcome this poor prognosis
。 For patients with mediastinal large B-cell lymphoma (PMBL), 6 courses of R-CHOEP-14 (rituximab + cyclophosphamide + doxorubicin + vincristine + etoposide + prednisone), 2 courses of DHAP (cisplatin+cytarab + dexamethasone) followed by 1-year PFS and OS with previous DA-EPOCH-R (dose-adjusted etoposide, doxorubicin, cyclophosphamide, vincristine, vincristine, Real-world outcomes such as prednisone plus rituximab) are comparable and well
tolerated.
For patient management in the COVID-19 era, the study found that the choice of pretreatment regimen had less impact on the effectiveness of the COVID-19 vaccine; The interval between vaccination and rituximab without infusion is at least 6 months, and the effect is better
.

Professor Lin Junfang made a report

During the discussion session, the discussion guests Professor Kong Fancong of the First Affiliated Hospital of Nanchang University and Professor Huang Yan of Jiangxi Provincial Cancer Hospital conducted in-depth discussions with Professor Lin Junfang on the issues of "Efficacy of Tandem Transplantation", "TEAM (Setepine + Etoposide + Cytarabine + Mefaron) Program, Bendamustine Combined BEAM (Carmustine + Etoposide + Cytarabine + Mephram) Program", "The Value of Double Transplantation for High-Risk Patients" and "New Drugs or Transplants Should Be Chosen When Lymphoma Recurs", etc.
, and the academic atmosphere was strong
。

Professor Yi Kun of Jiangxi Provincial Cancer Hospital gave a report
on the topic of "Clinical Application of PEG-rhG-CSF in Lymphoma Hematopoietic Stem Cell Transplantation".
Professor Yi Kun first analyzed the epidemiological data of lymphoma, and pointed out that compared with European and American countries, lymphoma patients in China are relatively younger, the incidence of aggressive lymphoma is high, patients need stronger combination chemotherapy regimens, and some patients need ASCT consolidation
.
Subsequently, Professor Yi Kun concluded through the interpretation of several articles that PEG-rhG-CSf can be used for the mobilization and reconstruction of bone marrow peripheral hematopoietic stem cell transplantation in MM and lymphoma patients, and the application effect in transplantation and reconstruction is not inferior to, or even better than, rhG-CSF
.
In addition, PEG-rhG-CSF is more economical
for reconstitution of peripheral hematopoietic stem cells for lymphoma after transplantation than rhG-CSF.

Professor Yi Kun made a report

Subsequently, Professor Lin Jianyang of Fujian Provincial Cancer Hospital and Professor Zhong Xingxing of Ganzhou People's Hospital participated in the discussion and had wonderful exchanges
with Professor Yi Kun on topics such as "the timing of the use of PEG-rhG-CSf in transplant patients and patients with conventional chemotherapy", "the dosage and safety of PEG-rhG-CSf".

Professor Liu Weiping of Peking University Cancer Hospital mentioned in the report "Progress of Lymphoma Autologous Transplantation" that ASCT is an important treatment strategy for lymphoma, and the current ASCT method is mature, well-documented, and accessible, and is suitable for most patients with
relapse refractory (R/R).
ASCT has a wide range of applications, in addition to prolonging the survival time of non-Hodgkin lymphoma (NHL) patients, the benefits for patients with R/R Hodgkin lymphoma (HL) can not be ignored
.
Research data from Professor Liu Weiping's Center show that compared with non-transplanted patients, the one-year OS rate of R/R HL patients in the transplant group increased by 11%, and the 2-year OS rate increased by 20%.

In the era of new drugs, various types of new drugs have played an important role in improving the remission rate and depth of remission of induction therapy, but new drugs cannot completely replace transplantation, and the use of transplantation for consolidation therapy can significantly improve patient PFS and OS
.
Issues such as the standardization of new drugs, new therapies and ASCT in combination are worth further exploration
in the future.

Professor Liu Weiping made a report

During the discussion session, Professor Tang Duozhuang of the Second Affiliated Hospital of Nanchang University and Professor Zhang Kejie of Zhongshan Hospital Affiliated to Xiamen University actively discussed
with Professor Liu Weiping on such issues as "the age of patients with recommended ASCT", "how to treat patients with primary central lymphoma who have failed to achieve complete remission after ASCT", "the efficacy of CAR-T and ASCT combined application", and "the development of mesenchymal stem cells and induced pluripotent stem cells".

The special case sharing session was wonderful and rewarding! This special session was presided over
by Professor Liu Tingbo of Union Hospital Affiliated to Fujian Medical University.

Professor Liu Tingbo served as the special host of case sharing

Professor Chen Changkun of Ganzhou People's Hospital shared a case
of ASCT treatment of recurrent intestinal NKTCL.
The patient, male, 46 years old, had previously undergone colon tumor surgery in an external hospital, pathological indications of NKTCL, and then used 6 courses of chemotherapy with a 6-course of cidilizumab + aluminatib + pementlease regimen (specific medication unknown).

After the recurrence, he was treated at Professor Chen Changkun and diagnosed with extranodal NK/T-cell lymphoma (ENKTCL) stage III; PINK score 3, high risk; PINK-E score 3, high risk; ECOG score 1 point
.
Combined with the actual situation of patients and the recommendations of domestic and foreign guidelines, ASCT
was selected after 3 courses of P-Gemox (pemantose-glycine + gemcitabine + oxaliplatin) regimen + PEG-rhG-CSF liter mobilization of hematopoietic stem cells + 1 course of P-Gemox regimen.
Maintenance therapy gives patients PD-1 monoclonal antibody plus sidabenamide, but due to a change in reimbursement policy, sidabenamide is replaced with thalidomide
.
Follow-up 14 months after ASCT found no tumor lesions
.
Finally, Professor Chen Changkun shared his experience that chemotherapy-sensitive R/R ENKTCL patients can benefit from ASCT.
PEG-rhG-CSF mobilizes peripheral hematopoietic stem cells to be safe and reliable
.

Professor Chen Changkun made a report

During the discussion session, Professor Peng Zhiqiang of Jiangxi Provincial Cancer Hospital and Professor Xu Wenqian of Quanzhou First Hospital had a heated discussion
with Professor Chen Changkun on issues such as "Specific Use Scheme of Cytarabine" and "Interval between PEG-rhG-CSF and Collection of Hematopoietic Stem Cells".
Professor Liu Tingbo commented and said that the patient's treatment process is standardized and the efficacy is good, and he looks forward to the announcement
of the follow-up situation.

Professor Luo Xiaofeng of Union Hospital Affiliated to Fujian Medical University shared the treatment process
of 1 case of T-LBL patient.
Patient, male, 24 years old, diagnosed in the hospital as T-LBL, Lugano stage IV; Hepatitis B virus carrying
.
1 course of VDLP regimen (vindesine + norethromycin + pementophose-+ prednisone), 1 course of CAN regimen (cyclophosphamide + cytarabine + 6-ponopurine), 2 courses of HD-MTX + 6-MP regimen (methotrexate: 5g D1, 8g D15+6-porosine: 40 mg D1-28) chemotherapy, during which bone marrow suppression, lung infection, drug-induced liver damage and even liver failure, hepatic encephalopathy and other symptoms have been repeatedly presented, and the patient's condition has improved after symptomatic treatment.
Efficacy evaluation for follow-up is partial remission
.
After Professor Luo Xiaofeng began to treat this patient, after comprehensive consideration, he successively gave chemotherapy with his reduction EA regimen (etoposide 150 mg D1-2 + cytarabine 1.
2g D1-3), VDLP reduction regimen (vincristine 2 mg D1 + daunorubicin 60 mg D1-3 + pementase 3759IU/m² D1 + dexamethasone 12.
5 mg D1-7), and CT review found that the anterior mediastinal poststernal mass was found, and the lymphoma may be large
。

Professor Luo Xiaofeng made a report

During the discussion session, Professor Lin Chuanming of the First Affiliated Hospital of Gannan Medical College and Professor Guo Jiangrui of Union Hospital Affiliated to Fujian Medical University discussed
issues such as "Patient Follow-up Chemotherapy Regimen Choice", "Feasibility of Radiotherapy" and "Possibility of Application of New Drugs and New Therapies such as Daretolizumab and CAR-T".
Professor Liu Tingbo said that the patient's condition in this case is complex, and the choice of treatment plan needs to be considered from many aspects, if the patient enters the bone marrow suppression state after chemotherapy or can be combined with PEG-rhG-CSF for supportive therapy, hematopoietic stem cell transplantation
can be performed if necessary.

At the end of the meeting, Professor Shuang Yuerong and Professor Shen Jianzhen summarized
the conference.
They said: Thank you for your wonderful sharing, this meeting is a complete success! At present, the proportion of patients who perform transplantation is still low, the combination of new drugs and transplantation still has no standard plan, and the exploration of future transplantation still needs to be not fanciful, not vain, and do it in practice! Doctors are benevolent and can better serve patients is our goal; The supremacy of life is our eternal belief
.
I hope that all doctors in the Department of Hematology can uphold their hearts, bring more well-being to patients with hematological tumors, and strive to achieve better clinical cures
.

Professor Shuang Yuerong summarized the meeting

Professor Shen Jianzhen summarized the meeting

Poke "Read the original article" to see more